Malabsorption syndrome

This phase 3 trial tests glepaglutide, a synthetic hormone given as a twice-weekly injection, in 90 adults with short bowel syndrome who rely on IV nutrition. The goal is to see if the drug can safely reduce the amount of IV support needed. Participants will be randomly assigned …

This study tests a device called RELiZORB that pre-digests fat in tube feedings for children with short bowel syndrome who rely on IV nutrition. The goal is to see if it helps them absorb more nutrients and reduce their need for IV feeding. About 32 children aged 2 to 18 will use…

This phase 2 trial tests crofelemer, a plant-based oral powder, in 18 adults with short bowel syndrome and intestinal failure who rely on IV nutrition. Participants receive either a low dose, a higher dose, or a placebo for 24 weeks. The goal is to see if crofelemer safely reduce…

This study tests a drug called ELGN-2112 in 60 very premature infants (born before 26 weeks) and growth-restricted infants (born 26-32 weeks). The goal is to see if the drug is safe compared to a placebo. If it works, it could help these fragile babies absorb nutrients better.

This study is testing an upgraded amino acid-based nutritional supplement for 30 children and adults who have severe gut problems like inflammatory bowel disease, short bowel syndrome, or severe allergies. Participants will use the supplement as part of their diet for 28 days. Re…

This study tests a drug called ELGN-2112 in preterm infants born between 26 and 32 weeks who have trouble absorbing food. The goal is to see if the drug helps them reach full feeding sooner compared to a placebo. About 360 babies will take part in this Phase 3 trial.